• linkedin
  • Increase Font
  • Sharebar

    An Opioid Story Earns a Pulitzer

    A reporter earned the biggest journalism prize covering the opioid crisis.

    Eric Eyre, a reporter with the Charleston (WVA) Gazette-Mail, won the 2017 Pulitzer Prize for Investigative Reporting for his series of articles on the opioid epidemic in West Virginia, written over several years.

    His opening line? “Follow the pills and you’ll find the overdose deaths.”  His series of articles exposed the flood of opioid drugs into West Virginia.

    Eyre wrote of how a town with a population under 400 had a pharmacy that received nearly 9 million hydrocodone pills in 2 years. The whole state received 780 million hydrocodone and oxycodone pills over 6 years, or 433 pills for every man, woman, and child. “One mom-and-pop pharmacy in Oceana received 600 times as many oxycodone pills as the Rite Aid drugstore just eight blocks away.” Regulations to help control the flow of prescription opioids by spotting suspiciously high shipments were not enforced.

    Related article: The Trump Administration Gets Tough on Opioids

    Eyre also told the stories of families broken by painkiller addictions.

    The citation from the Pulitzer committee called Eyre’s reporting courageous because it was done in the face of powerful opposition. Drug wholesalers and distributors fought to keep their sales number secret and denied they played a role in the state’s epidemic.

    You can read the Pulitzer citation here, which has links to the articles that won Eyre the prize of $15,000.

    Eyre is statehouse reporter for the Gazette-Mail. He has won several other journalism awards, including the Investigative Reporters & Editors Medal and the National Headliners Award. 

    Valerie DeBenedette
    Valerie DeBenedette is Managing Editor of Drug Topics.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available